title: [Mediastinal seminoma. Is it an entity to be treated differently?].
abstract: The evolution of the therapeutic concepts of non seminomatous tumours (T) has chemotherapy as the preponderant treatment, and has also led to a different approach for mediastinal seminomas. In effect the traditional attitude for as complete an excision as possible followed by radiotherapy is in the process of changing. Certainly in 20% of cases a complete excision is possible. Post operative radiotherapy (30-50 grays) does not seem to change the survival and may be questioned in the management of invasive T. The radical debulking surgery of varying degrees no longer has a place. The standard treatment of inoperable T has remained for some time radiotherapy (35-40 grays). The survival at 5 years for these patients is around 60%, very close to the stage IIB seminoma of the testicles. If the seminoma seems to be radiosensitive it is also chemo-sensitive with an RC less than 80% in advance seminomas and of 90% in mediastinal seminomas. Thus there appears to be a contradictory debate; in the absence of precise staging of "thymic type" tumour and of randomised trials made difficult by the small number of cases one can envisage the following option: In the case of an inoperable T radiotherapy alone, excepting in the very bulky forms (diameter greater than 50% of the chest) or metastases where primary chemotherapy (CT) (4 cycles of VP16-platine) has a place: The treatment of the residual mass after CT depends on the size of the latter: less than 3 or equal to 3 cm by complementary treatment and greater than 3 cm by secondary surgery and if the seminoma is active complementary.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Département de Médecine, Institut Gustave-Roussy, Villejuif.
authors.forename: P
authors.initials: P
authors.lastname: Ruffié
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002985:Clinical Protocols / Q000592:standards*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003663:Decision Trees; D004407:Dysgerminoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008479:Mediastinal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D009367:Neoplasm Staging; D011159:Population Surveillance; D011379:Prognosis; D011878:Radiotherapy / Q000592:standards; D013514:Surgical Procedures, Operative / Q000592:standards; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
vernacular_title: Séminome médiastinal. Est-ce une entité à traiter différemment?